Clinical trials: insulin glargine
Cystic Fibrosis Related Diabetes
Insulin Glargine Vs Standard Insulin Therapy
This Study is designed to determine whether treatment of CFRD with glargine insulin will improve hemoglobin A1c, weight and muscle mass compared to the traditional regimen of bedtime NPH insulin.
- Trial name
- NCT00222521
- Testing
- Glargine insulin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Minnesota
Kidney Transplantation, Diabetes
IV Insulin Protocol in Diabetes and Renal Transplantation
Purpose: The purpose of this study is to provide tight blood sugar control using insulin given through the veins at the time of kidney transplantation and up to 3 days after surgery.
- Conditions
- Kidney Transplantation, Diabetes, Hyperglycemia
- Trial name
- NCT00609986
- Testing
- insulin, NPH Insulin or glargine insulin and aspartame insulin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Medical University of South Carolina
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.
- Trial name
- LixiLan-G (NCT02787551)
- Testing
- Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide
- Where
- 124 sites in United States, Canada and 7 more
- Volunteers
- 514 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
Primary Objective: Percentage of patients achieving Glycosylated Hemoglobin (HbA1c) < 7% with no severe or nocturnal hypoglycemic episodes at 6 months Secondary Objectives: Glycosylated Hemoglobin (HbA1c) change from baseline to…
- Trial name
- AFICIONADO (NCT01127269)
- Testing
- INSULIN GLARGINE
- Where
- 23 sites in Argentina
- Volunteers
- 178 people
- Sponsor
- Sanofi
Asthma, Diabetes Mellitus
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics with Asthma
- Trial name
- NCT00139659
- Testing
- Inhaled Insulin, Subcutaneous Insulin
- Where
- 102 sites in United States, Brazil and 3 more
- Volunteers
- 288 people
- Sponsor
- Pfizer
Diabetes Mellitus
Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes
The current trial will examine the efficacy and safety of Exubera administered as a mealtime insulin compared to lispro, when added to an existing regimen of basal insulin glargine + or = Oral Agents (OAs).
- Trial name
- NCT00348374
- Testing
- Insulin Lispro, Exubera
- Where
- 63 sites in United States, Puerto Rico
- Volunteers
- 191 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes.
- Trial name
- NCT03922750
- Testing
- Insulin icodec, Insulin glargine U100
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 154 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog.
- Trial name
- NCT02767596
- Testing
- Lixisenatide, Basal insulins
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Laniado Hospital
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary Objective: To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in…
- Trial name
- Lixilan-L-CN (NCT03798080)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin
- Where
- 45 sites in China
- Volunteers
- 426 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine
Primary Objective: To demonstrate significant reduction in postprandial plasma glucose (ΔAUC0:30-4:30h) after a standardized breakfast from baseline to Day 29.
- Trial name
- NCT02200991
- Testing
- LIXISENATIDE AVE0010, Sitagliptin, Insulin glargine HOE901
- Where
- 20 sites in Japan
- Volunteers
- 136 people
- Sponsor
- Sanofi
Hyperglycemia, Stroke, Acute
Insulin for Hyperglycemia in Stroke Trial
Introduction: Glycemic control in acutely ill stroke patients with hyperglycemia is vital. Although insulin is the choice of anti-diabetic agent during acute stage, it is not clear which insulin regimen is better in terms of…
- Trial name
- NCT04834362
- Testing
- Analog Insulin, Human insulin
- Where
- Bangladesh
- Volunteers
- 452 people
- Sponsor
- National Institute of Neurosciences and Hospital, Dhaka
Diabetic Ketoacidosis, Type 1 Diabetes
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04567225
- Testing
- Early Glargine, Late Glargine, IV insulin infusion
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Type 2
Insulin Glulisine in Diabetes Mellitus, Type 2
Primary objective: The primary study objective is to demonstrate superior efficacy of an intensified insulin regimen with insulin glulisine and insulin glargine to a two-injection conventional insulin regimen in terms of change…
- Trial name
- GINGER (NCT00174668)
- Testing
- Insulin Glulisine, Insulin Therapy, Insulin Glargine
- Where
- 15 sites in Australia, Belgium and 13 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Adult Patients With Type 2 Diabetes
A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes
To compare the efficacy and safety of HR17031 injection and insulin glargine, including the changes of efficacy indicators such as HbA1c, fasting blood glucose, body weight and safety indicators such as adverse events and…
- Trial name
- NCT06871761
- Testing
- HR17031 injection, insulin glargine
- Where
- China
- Volunteers
- 393 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes Mellitus (T2DM)
A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes
Primary objective: Glycemic control after initiation or switch to insulin glargine 300 U/ml in everyday clinical practice Secondary objective: Treatment satisfaction
- Trial name
- ELDERLY-T (NCT05607160)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients
Primary Objective: The primary objective of this study is to obtain efficacy and safety descriptive data on 2 different titration algorithms: the INSIGHT titration algorithm (self-titration of 1 unit/day) and the EDITION trial…
- Trial name
- TITRATION (NCT02401243)
- Testing
- INSULIN GLARGINE (U300)
- Where
- 25 sites in Canada
- Volunteers
- 253 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
Gan & Lee Insulin Glargine Target Type (1) Evaluating Research
Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER1 (NCT03371082)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 85 sites in United States, Czechia and 4 more
- Volunteers
- 576 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Diabetes Mellitus, Type 1 Diabetes
Closed Loop From Onset in Type 1 Diabetes
The purpose of the study is to use a novel treatment approach, the artificial pancreas, after diagnosis of type 1 diabetes (T1D) to improve glucose control with the anticipated improvements of residual C-peptide secretion.
- Trial name
- CLOuD (NCT02871089)
- Testing
- Closed-loop system (Florence M or CamAPS FX), Multiple Daily Injections
- Where
- 7 sites in United Kingdom
- Volunteers
- 96 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Type 2
Self Titration With Apidra to Reach Target Study (START)
Primary Objective: The primary objective of this study is to demonstrate non-inferiority of a patient-managed titration algorithm (including blood glucose monitoring) for the addition of a single dose of insulin glulisine at…
- Trial name
- NCT01013571
- Testing
- insulin glargine, Apidra (insulin glulisine)
- Where
- Canada
- Volunteers
- 493 people
- Sponsor
- Sanofi
Type 2 Diabetes
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
Primary objective: To evaluate the effect of lixisenatide versus placebo over a period of 24 weeks on glycemic control, as evaluated by glycosylated hemoglobin (HbA1c) reduction, in older type 2 diabetes participants (T2DM) who…
- Trial name
- GetGoal-O (NCT01798706)
- Testing
- Lixisenatide (AVE0010), Antidiabetic background therapy
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Sanofi